ArticleOncoTargets and therapy2016

Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?

Thomas P Shakespeare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.